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Pasteurella Vaccination of Ewes
Abstract
Pasteurella haemolytica is a major contributor to neonatal pneumonia in lambs; which continues to be a
major problem. Experimentation was conducted to determine the efficacy of vaccinating pregnant ewes to
reduce the incidence of pneumonia in newborn lambs. Vaccines utilized in this experimentation included
three different commercial Pasteurella haemolytica vaccines intended for use in cattle and an experimental
vaccine prepared in our laboratory. Only one of the commercial vaccines increased levels of anti-Pasteurella
antibodies in serum of the ewes at time of lambing, but lambs from all three groups of vaccinated ewes had
higher levels of antibodies than control lambs. Some lambs in all groups developed pneumonia during the
neonatal period.
Ewes administered the experimental vaccine had significantly higher levels of serum antibodies at lambing
time. This increase was reflected in increased levels in serum of lambs from the vaccinated ewes. However, the
antibodies appeared not to be protective, since as many lambs in the treatment group developed pneumonia
as did in the control group.
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Summary
Pasteurella haemolytica is a major contributor to
neonatal pneumonia in lambs; which continues to be
a major problem.  Experimentation was conducted to
determine the efficacy of vaccinating pregnant ewes
to reduce the  incidence of pneumonia in newborn
lambs.  Vaccines utilized in this experimentation
included three different commercial Pasteurella
haemolytica vaccines intended for use in cattle and
an experimental vaccine prepared in our laboratory.
Only one of the commercial vaccines increased levels
of anti-Pasteurella antibodies in serum of the ewes at
time of lambing, but lambs from all three groups of
vaccinated ewes had higher levels of antibodies than
control lambs.  Some lambs in all groups developed
pneumonia during the neonatal period.
Ewes administered the experimental vaccine had
significantly higher levels of serum antibodies at
lambing time.  This increase was reflected in
increased levels in serum of lambs from the
vaccinated ewes.  However, the antibodies appeared
not to be protective, since as many lambs in the
treatment group developed pneumonia as did in the
control group.
Introduction
Neonatal pneumonia continues to be a major
problem in Iowa sheep flocks.  Pasteurella haemolytica
bacteria of several serotypes of the A biotype are the
primary cause of this disease.  The pneumonia occurs
most commonly during the first three weeks of life and
may be responsible for appreciable mortality in some
flocks.  Management practices and early treatment may
control the disease to some extent, but better methods
are needed.
Vaccination incorporated into management
practices is one potential method for controlling this
disease.  If resistance of the lambs could be enhanced
through antibodies transferred from the ewe, beneficial
effects might be expected.  This approach requires a
vaccine that enhances the level of protective antibodies
in the ewe and results in increased transfer of those
antibodies to the newborn lamb via the colostrum.  No
commercial vaccine currently is available for use in
sheep.  The problem is complicated by the multiple
serotypes of P. haemolytica contributing to pneumonia in
lambs.  Furthermore, the specificity of antibodies
primarily responsible for protecting against P.
haemolytica infection remains somewhat controversial.
Researchers have reported immunity to be type specific
and mediated by capsular, outer membrane protein or
leukotoxin antibodies.  A new generation of Pasteurella
vaccines for use in cattle are based on the potential
immunogenicity of bacterial extracts and leukotoxin
included in the preparations.  A problem with their use in
sheep is that they are composed of antigenic material
from a single serotype, Pasteurella haemolytica A-1.
A question commonly posed by sheep producers has
been as follows:  Can the cattle vaccine be used to
protect sheep?  This study was conducted to determine
the efficacy of commercial Pasteurella vaccines and an
experimental vaccine prepared in our laboratory.
Materials and Methods
Ewes in the McNay Farm flock scheduled to lamb in
February were randomly assigned to treatment groups.
These ewes were either vaccinated or left as
unvaccinated controls.  Vaccines were administered
following collection of blood for serum in mid-January,
and the ewes and their lambs were bled for serum 24 to
48 hours after lambing.  Serum was harvested and stored
at -20 ° C until tested for antibodies.
Experiment I was conducted in 1994 with treatment
groups of 10 animals each as follows:
A - commercial vaccine A
B - commercial vaccine B
C - commercial vaccine C
D - controls, no vaccination.
One-half the recommended cattle dose (2 ml.) was
administered with 0.5 ml. injected subcutaneously on
each side of the neck.
Experiment II was conducted in 1995 with treatment
groups as follows:
A - 23 ewes, administered 0.5 ml. experimental
vaccine subcutaneously at each of two sites
B - 23 ewes, no vaccination
The vaccine consisted of equal amounts of sodium
salycylate-extracted outer membrane constituents of four
Pasteurella haemolytica organisms representing serotypes
1, 2, 6, and 8.  Dosage per ewe was 1 mg. of protein in
0.5 ml. saline solution emulsified in 0.5 ml. of Freund’s
incomplete adjuvant.
Antibody titers in sera of ewes and lambs were
determined with an ELISA.  The antigen utilized for
testing sera from Experiment I was from a serotype A-1
culture.  The antigen was prepared by suspending
organisms grown on agar medium in RPMI 1640 medium,
treatment with sodium salicylate, removal of the bacteria
by centrifugation, dialysis against tris-buffered saline
solution, and precipitation with cold ethanol.  Antigen
utilized for Experiment II was prepared by the same
procedure but represented a pool made of equal
quantities of extract from the four different serotypes.
The number of animals utilized for analysis of data was
reduced from the number in the original groups.  Only
combinations of ewes and surviving lambs where testing
indicated nursing and transfer of maternal antibodies are
included in the reported findings.
Results and Discussion
Most of the ewes had relatively high titers of
antibodies against outer membrane components of P.
haemolytica prior to vaccination, although there was
marked variability among animals.  These antibody
levels are indicated in figures 1, 2, and 3 where the titer
is reported as the positive/negative ratio (a P/N ratio of
25 reflects a titer of approximately 1:14,000).
In experiment I, only one of the commercial
vaccines significantly enhanced the titer of the ewes at
time of lambing and could be due in part to the relatively
low mean titer in that group of ewes prior to vaccination.
Antibody levels in serum of ewes at the time of lambing
may be somewhat misleading, since large quantities of
immunoglobulins are transferred to the colostrum during
the last three weeks of gestation.  This is reflected in the
levels of antibodies in lambs from vaccinated ewes,
which were significantly higher than in lambs from
unvaccinated ewes.  These antibodies, however, did not
appear to be protective since pneumonia developed in
lambs from all groups (Table 1).  Lambs developing
pneumonia had moderate levels of antibodies, levels that
were higher than some lambs that were not diagnosed
with clinical pneumonia.
The experimental vaccine utilized in experiment II
markedly enhanced antibody levels in vaccinated ewes
and their lambs (figure 3).  The response of the ewes and
transfer to the lambs was better than with the commercial
vaccines utilized in experiment I.  However, once again
these antibodies did not seem to protect the lambs from
clinical pneumonia, since 19 lambs developed clinical
pneumonia—9 from control ewes and 10 from vaccinated
ewes.
The susceptibility of lambs to P. haemolytica
pneumonia when they have appreciable levels of
antibodies to the microorganism presents a dilemma.
One would expect those antibodies to be protective but
this seems not to be the case.  Possible reasons for this
circumstance are as follows: (1)  the specificity of the
antibodies and (2)  the isotype of the antibodies.  By far
the highest level of antibodies transferred from the ewe to
her lambs belong to the IgG1 isotype.  Protective
antibodies (anti-leukotoxin?) may be present in the ewe
but may be primarily of the IgG2 isotype and
consequently are not efficiently transferred to the lambs.
This needs to be confirmed by additional
experimentation.  The answer to the problem may be a
vaccine that will induce a high level of protective
antibodies of the IgG1 isotype in the ewe.
Figure 1.  Mean antibody titers of ewes before vaccination with
commercial Pasteurella haemolytica vaccines and after lambing.
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Figure 2.  Mean antibody titers in ewes before vaccination with commercial 
vaccines and their lambs after nursing.
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Figure 3.  Serum antibody titers of ewes pre- and post vaccination with an 
experimental vaccine and their lambs after nursing.
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Table 1.  Mean antibody levels in all lambs compared with levels in lambs that
subsequently developed clinical pneumonia.
All          Lambs Pneumonic    Lambs
Mean Ab Mean Ab
Group Total Titer     Number Titer
Controls 19 8.9 2 3.9
Vaccine A 11 19.5 2 15.8
Vaccine B 11 19.5 1 8
Vaccine C 14 19.1 2 20.8
